Resumen

Objective: To evaluate the effect of liraglutide administration on body mass index in obese adolescents 15 to 18 years of age. Patients and methods: A quasi-experimental study was conducted in 18 obese patients without prior drug treatment. Patients received 0.6 mg of subcutaneous liraglutide once per day during the first eight days of treatment and then 1.2 mg/day up to day 48. Body mass index, blood pressure, and metabolic profile were assessed before and after the pharmacological intervention. Results:There was a significant decrease in body weight (78.8 [72.8-85.1] vs. 77.7 [72.0-82.5] kg; p = 0.001), body mass index (28.7 [27.6-31.6] vs. 27.7 [26.6-30.6] kg/m²; p = 0.001), waist circumference (96.0 [89.2-102.7] vs. 91.0 [87.5-99.5] cm; p = 0.001), and adiposity (38.2 [34.5-41.4] vs. 35.8 [30.3-39.8] %; p = 0.003) after 48 days of liraglutide administration. Conclusions: Liraglutide decreases body weight, body mass index, waist circunferente, and adiposity in obese adolescents.

Palabras clave: Adolescents liraglutide obesity

2017-05-23   |   217 visitas   |   Evalua este artículo 0 valoraciones

Vol. 3 Núm.3. Julio-Septiembre 2016 Pags. 124-128 Rev Mex Endocrinol Metabol Nut 2016; 3(3)